Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.48 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573600 | 0.92 | TRPV1 (0.49) | TRPV1LIMK2PDGFRB | |
| SCHEMBL12251021 | 0.91 | P2RY12 (0.49) | LIMK2PDGFRBKIT | |
| SCHEMBL12251013 | 0.90 | PDGFRB (0.45) | PDGFRB | |
| SCHEMBL5569274 | 0.85 | LIMK2 (0.51) | LIMK2PDGFRBKIT | |
| SCHEMBL2381747 | 0.84 | TRPV1 (0.47) | TRPV1LIMK2PDGFRBKITPDGFRA | |
| SCHEMBL2385195 | 0.83 | PDGFRB (0.44) | TRPV1PDGFRBKIT | |
| SCHEMBL2401520 | 0.83 | MEN1 (0.50) | PDGFRB | |
| SCHEMBL12251049 | 0.80 | DRD2 (0.41) | TRPV1PDGFRB | |
| SCHEMBL2383895 | 0.79 | TRPV1 (0.52) | TRPV1LIMK2PDGFRB | |
| SCHEMBL2383727 | 0.78 | DRD2 (0.51) | PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | TRPV1 4108/4885LIMK2 328/4885PDGFRB 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.